{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:50:17Z","timestamp":1793155817310,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s13555-024-01255-4","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T02:02:30Z","timestamp":1727143350000},"page":"2739-2757","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence"],"prefix":"10.1007","volume":"14","author":[{"given":"Piergiorgio","family":"Malagoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Dapavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Amerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Atzori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Bardazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Chiricozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Congedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Giofr\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Lembo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Loconsole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Mazzocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santo Raffaele","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Morrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Offidani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Palazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Parodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pellacani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Piaserico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Potenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Prignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Savoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Stingeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Travaglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Trovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Zichichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"key":"1255_CR1","first-page":"13","volume":"10","author":"J Bu","year":"2022","unstructured":"Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of psoriasis and comorbid diseases: a narrative review. Front Immunol. 2022;10:13.","journal-title":"Front Immunol"},{"issue":"2","key":"1255_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Investig Dermatol. 2013;133(2):377\u201385.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"1255_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/abd1806-4841.20153038","volume":"90","author":"MFSP de Oliveira","year":"2015","unstructured":"de Oliveira MFSP, Rocha BO, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9\u201320.","journal-title":"An Bras Dermatol"},{"issue":"1","key":"1255_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jid.2017.07.841","volume":"138","author":"MH Noe","year":"2018","unstructured":"Noe MH, Shin DB, Wan MT, Gelfand JM. Objective measures of psoriasis severity predict mortality: a prospective population-based cohort study. J Investig Dermatol. 2018;138(1):228\u201330.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"1255_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1477-7525-4-35","volume":"4","author":"MJ Bhosle","year":"2006","unstructured":"Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4(1):35.","journal-title":"Health Qual Life Outcomes"},{"issue":"10281","key":"1255_CR6","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. The Lancet. 2021;397(10281):1301\u201315.","journal-title":"The Lancet"},{"key":"1255_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2147\/ITT.S240891","volume":"10","author":"M Mosca","year":"2021","unstructured":"Mosca M, Hong J, Hadeler E, Hakimi M, Liao W, Bhutani T. The role of IL-17 cytokines in psoriasis. Immunotargets Ther. 2021;10:409\u201318.","journal-title":"Immunotargets Ther"},{"issue":"1","key":"1255_CR8","first-page":"47","volume":"19","author":"S Xu","year":"2021","unstructured":"Xu S, Gao X, Deng J, Yang J, Pan F. Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis. J Deutschen Derma Gesell. 2021;19(1):47\u201356.","journal-title":"J Deutschen Derma Gesell."},{"issue":"2","key":"1255_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s13555-021-00483-2","volume":"11","author":"A Menter","year":"2021","unstructured":"Menter A, Krueger GG, Paek SY, Kivelevitch D, Adamopoulos IE, Langley RG. Interleukin-17 and Interleukin-23: a narrative review of mechanisms of action in psoriasis and associated comorbidities. Dermatol Ther (Heidelb). 2021;11(2):385\u2013400.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1255_CR10","first-page":"14","volume":"11","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Malagoli P, Balato A, Bardazzi F, Burlando M, et al. Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses \u2013 IL PSO (Italian landscape psoriasis). Front Immunol. 2024;11:14.","journal-title":"Front Immunol"},{"issue":"1","key":"1255_CR11","first-page":"34","volume":"22","author":"L Mastorino","year":"2024","unstructured":"Mastorino L, Dapavo P, Susca S, Cariti C, Siliquini N, Verrone A, et al. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment. J der Deutschen Dermatologischen Gesellschaft. 2024;22(1):34\u201342.","journal-title":"J der Deutschen Dermatologischen Gesellschaft."},{"issue":"5","key":"1255_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40265-024-02028-1","volume":"84","author":"SE Thomas","year":"2024","unstructured":"Thomas SE, Barenbrug L, Hannink G, Seyger MMB, de Jong EMGJ, van den Reek JMPA. Drug survival of IL-17 and IL-23 inhibitors for psoriasis: a systematic review and meta-analysis. Drugs. 2024;84(5):565\u201378.","journal-title":"Drugs"},{"key":"1255_CR13","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.2147\/CCID.S416149","volume":"16","author":"F Russo","year":"2023","unstructured":"Russo F, Galluzzo M, Stingeni L, Persechino S, Zichichi L, Conti A, et al. Long-term drug survival and effectiveness of secukinumab in patients with moderate to severe chronic plaque psoriasis: 42-month results from the SUPREME 2.0 study. Clin Cosmet Investig Dermatol. 2023;16:3561\u201374.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1255_CR14","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2200868","author":"S Dastoli","year":"2023","unstructured":"Dastoli S, Passante M, Loconsole F, Mortato E, Balato A, Piccolo V, et al. Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy. J Dermatol Treat. 2023. https:\/\/doi.org\/10.1080\/09546634.2023.2200868.","journal-title":"J Dermatol Treat"},{"key":"1255_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107925","volume":"229","author":"F Kolbinger","year":"2022","unstructured":"Kolbinger F, Di Padova F, Deodhar A, Hawkes JE, Huppertz C, Kuiper T, et al. Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: physical and pharmacological properties underlie the observed clinical efficacy and safety. Pharmacol Ther. 2022;229: 107925.","journal-title":"Pharmacol Ther"},{"key":"1255_CR16","unstructured":"European Medicines Agency. Cosentyx, INN-secukinumab - European Medicines Agency - Product information [Internet]. [cited 2024 Feb 11]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_en.pdf"},{"issue":"6","key":"1255_CR17","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bjd.20971","volume":"186","author":"M Augustin","year":"2022","unstructured":"Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, et al. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial*. Br J Dermatol. 2022;186(6):942\u201354.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1255_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/2040622317738910","volume":"9","author":"J Frieder","year":"2018","unstructured":"Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 2018;9(1):5\u201321.","journal-title":"Ther Adv Chronic Dis"},{"issue":"1","key":"1255_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","volume":"75","author":"PCM van de Kerkhof","year":"2016","unstructured":"van de Kerkhof PCM, Griffiths CEM, Reich K, Leonardi CL, Blauvelt A, Tsai TF, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83-98.e4.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1255_CR20","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjd.12214","volume":"168","author":"KA Papp","year":"2013","unstructured":"Papp KA, Griffiths CEM, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844\u201354.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1255_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","volume":"21","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"1255_CR22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A. The immunologic role of il-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379\u201390.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1255_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15599","author":"J Liang","year":"2022","unstructured":"Liang J, Zhang S, Li Q, Yu Y, Chen X, Zhang X. Review of secukinumab-induced adverse events of special interest and its potential pathogenesis. Dermatol Ther. 2022. https:\/\/doi.org\/10.1111\/dth.15599.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1255_CR24","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/s41598-023-50013-7","volume":"14","author":"V Eshwar","year":"2024","unstructured":"Eshwar V, Kamath A. Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database. Sci Rep. 2024;14(1):1222.","journal-title":"Sci Rep"},{"issue":"3","key":"1255_CR25","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13555-024-01122-2","volume":"14","author":"R Sun","year":"2024","unstructured":"Sun R, Bustamante M, Gurusamy VK, Lebwohl M, Gottlieb AB, Mease PJ, et al. Safety of secukinumab from 1 million patient-years of exposure: experience from post-marketing setting and clinical trials. Dermatol Ther (Heidelb). 2024;14(3):729\u201343.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1255_CR26","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40744-022-00434-z","volume":"9","author":"JF Merola","year":"2022","unstructured":"Merola JF, McInnes IB, Deodhar AA, Dey AK, Adamstein NH, Quebe-Fehling E, et al. Effect of secukinumab on traditional cardiovascular risk factors and inflammatory biomarkers: post hoc analyses of pooled data across three indications. Rheumatol Ther. 2022;9(3):935\u201355.","journal-title":"Rheumatol Ther"},{"issue":"5","key":"1255_CR27","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","volume":"139","author":"E von Stebut","year":"2019","unstructured":"von Stebut E, Reich K, Tha\u00e7i D, Koenig W, Pinter A, K\u00f6rber A, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Investig Dermatol. 2019;139(5):1054\u201362.","journal-title":"J Investig Dermatol"},{"issue":"2","key":"1255_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3109\/09546634.2014.880396","volume":"26","author":"G Girolomoni","year":"2015","unstructured":"Girolomoni G, Griffiths CEM, Krueger J, Nestle FO, Nicolas JF, Prinz JC, et al. Early intervention in psoriasis and immune-mediated inflammatory diseases: a hypothesis paper. J Dermatol Treat. 2015;26(2):103\u201312.","journal-title":"J Dermatol Treat"},{"key":"1255_CR29","first-page":"9","volume":"1","author":"PAO Felix","year":"2022","unstructured":"Felix PAO, Sampaio AL, Silva BL, Viana ALP. Early intervention in psoriasis: Where do we go from here? Front Med (Lausanne). 2022;1:9.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"1255_CR30","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","volume":"144","author":"JG Krueger","year":"2019","unstructured":"Krueger JG, Wharton KA, Schlitt T, Suprun M, Torene RI, Jiang X, et al. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. J Allergy Clin Immunol. 2019;144(3):750\u201363.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1255_CR31","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/bjd.12070","volume":"168","author":"P Rich","year":"2013","unstructured":"Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168(2):402\u201311.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1255_CR32","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/jdv.16180","volume":"34","author":"M Augustin","year":"2020","unstructured":"Augustin M, Jullien D, Martin A, Peralta C. Real-world evidence of secukinumab in psoriasis treatment\u2014a meta-analysis of 43 studies. J Eur Acad Dermatol Venereol. 2020;34(6):1174\u201385.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"1255_CR33","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1111\/jdv.12359","volume":"28","author":"C Paul","year":"2014","unstructured":"Paul C, Reich K, Gottlieb AB, Mrowietz U, Philipp S, Nakayama J, et al. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. J Eur Acad Dermatol Venereol. 2014;28(12):1670\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1255_CR34","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/1346-8138.13911","volume":"44","author":"M Ohtsuki","year":"2017","unstructured":"Ohtsuki M, Morita A, Igarashi A, Imafuku S, Tada Y, Fujita H, et al. Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: a prospective study to evaluate direct switch. J Dermatol. 2017;44(10):1105\u201311.","journal-title":"J Dermatol"},{"issue":"11","key":"1255_CR35","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1111\/jdv.14979","volume":"32","author":"L Iversen","year":"2018","unstructured":"Iversen L, Eidsmo L, Austad J, de Rie M, Osmancevic A, Skov L, et al. Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification \u2013 rationale and design of the randomized, multicenter STEPI n study. J Eur Acad Dermatol Venereol. 2018;32(11):1930\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1255_CR36","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/jdv.18846","volume":"37","author":"L Iversen","year":"2023","unstructured":"Iversen L, Conrad C, Eidsmo L, Costanzo A, Narbutt J, Pinter A, et al. Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study. J Eur Acad Dermatol Venereol. 2023;37(5):1004\u201316.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1255_CR37","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/jdv.19236","volume":"37","author":"K Sch\u00e4kel","year":"2023","unstructured":"Sch\u00e4kel K, Reich K, Asadullah K, Pinter A, Jullien D, Weisenseel P, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol. 2023;37(10):2016\u201327.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1255_CR38","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","volume":"156","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis. JAMA Dermatol. 2020;156(6):649.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1255_CR39","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s13555-022-00740-y","volume":"12","author":"B Strober","year":"2022","unstructured":"Strober B, Patil D, McLean RR, Moore-Clingenpeel M, Guo N, Levi E, et al. Utilization trends and impact of secukinumab treatment on clinical outcomes in biologic-naive patients with psoriasis in a US real-world setting. Dermatol Ther (Heidelb). 2022;12(6):1351\u201365.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1255_CR40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/14712598.2020.1708897","volume":"20","author":"M Galluzzo","year":"2020","unstructured":"Galluzzo M, D\u2019Adamio S, Silvaggio D, Lombardo P, Bianchi L, Talamonti M. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opin Biol Ther. 2020;20(2):173\u201382.","journal-title":"Expert Opin Biol Ther"},{"key":"1255_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13006","author":"N Rompoti","year":"2019","unstructured":"Rompoti N, Katsimbri P, Kokkalis G, Boumpas D, Ikonomidis I, Theodoropoulos K, et al. Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: a 104-week clinical study. Dermatol Ther. 2019. https:\/\/doi.org\/10.1111\/dth.13006.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1255_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001519","volume":"7","author":"R Ramonda","year":"2021","unstructured":"Ramonda R, Lorenzin M, Carriero A, Chimenti MS, Scarpa R, Marchesoni A, et al. Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. RMD Open. 2021;7(1): e001519.","journal-title":"RMD Open"},{"issue":"3","key":"1255_CR43","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/jvc2.185","volume":"2","author":"FJ Melgosa Ramos","year":"2023","unstructured":"Melgosa Ramos FJ, Mateu Puchades A, Guill\u00e9n Climent S, Galarreta Pascual M, Sa\u00e9z Bell\u00f3 M, Mart\u00ednez Ferrer MA, et al. Long-term secukinumab efficacy and safety in bio-na\u00efve patients with moderate-to-severe cutaneous psoriasis: a real-world retrospective noninterventional multicentric experience (128 patients). JEADV Clin Pract. 2023;2(3):576\u201382.","journal-title":"JEADV Clin Pract"},{"issue":"2","key":"1255_CR44","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s13555-022-00870-3","volume":"13","author":"M Gooderham","year":"2023","unstructured":"Gooderham M, Papp KA, Lynde C, Delorme I, Beecker J, Albrecht L, et al. Sustained effectiveness of secukinumab across different body regions in patients with moderate-to-severe plaque psoriasis from the PURE registry. Dermatol Ther (Heidelb). 2023;13(2):535\u201353.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7","key":"1255_CR45","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00403-024-03122-w","volume":"316","author":"KA Papp","year":"2024","unstructured":"Papp KA, Gooderham M, Lynde C, Brassard D, Al-Mohammedi F, Prajapati VH, et al. Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry. Arch Dermatol Res. 2024;316(7):362.","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"1255_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12895-020-00099-7","volume":"20","author":"A Egeberg","year":"2020","unstructured":"Egeberg A, See K, Garrelts A, Burge R. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort. BMC Dermatol. 2020;20(1):3.","journal-title":"BMC Dermatol"},{"issue":"3","key":"1255_CR47","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","volume":"21","author":"A Raharja","year":"2021","unstructured":"Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med. 2021;21(3):170\u20133.","journal-title":"Clin Med"},{"issue":"9","key":"1255_CR48","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1080\/14712598.2023.2236023","volume":"23","author":"L Mastorino","year":"2023","unstructured":"Mastorino L, Burzi L, Frigatti G, Fazio A, Celoria V, Macagno N, et al. Clinical effectiveness of IL-17 and IL-23 inhibitors on difficult-to-treat psoriasis areas (scalp, genital, and palmoplantar sites): a retrospective, observational, single-center, real-life study. Expert Opin Biol Ther. 2023;23(9):929\u201336.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"1255_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2015.04.011","volume":"73","author":"U Mrowietz","year":"2015","unstructured":"Mrowietz U, Leonardi CL, Girolomoni G, Toth D, Morita A, Balki SA, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(1):27\u201336 (e1).","journal-title":"J Am Acad Dermatol"},{"key":"1255_CR50","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12589","author":"JF Merola","year":"2018","unstructured":"Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018. https:\/\/doi.org\/10.1111\/dth.12589.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1255_CR51","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/14712598.2022.2029841","volume":"22","author":"M Galluzzo","year":"2022","unstructured":"Galluzzo M, Talamonti M, Atzori L, Bardazzi F, Campanati A, Di Cesare A, et al. Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study. Expert Opin Biol Ther. 2022;22(4):547\u201354.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"1255_CR52","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1402a119","volume":"14","author":"E Kyrmanidou","year":"2024","unstructured":"Kyrmanidou E, Kemanetzi C, Stavros C, Trakatelli MG, Patsatsi A, Madia X, et al. A real-life 208 week single-centred, register-based retrospective study assessing secukinumab survival and long-term efficacy and safety among Greek patients with moderate to severe plaque psoriasis, including difficult-to-treat manifestations such as genitals and scalp. Dermatol Pract Concept. 2024;14(2): e2024119.","journal-title":"Dermatol Pract Concept"},{"issue":"3","key":"1255_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.465","volume":"87","author":"J Krueger","year":"2022","unstructured":"Krueger J, Langley R, Nigen S. 35098 Secukinumab versus guselkumab in the treatment of ustekinumab-resistant psoriatic plaques: 16-week randomized, open-label, multicenter ARROW study. J Am Acad Dermatol. 2022;87(3): AB108.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1255_CR54","doi-asserted-by":"publisher","first-page":"e574","DOI":"10.1111\/jdv.18069","volume":"36","author":"G Avallone","year":"2022","unstructured":"Avallone G, Cariti C, Dapavo P, Ortoncelli M, Conforto L, Mastorino L, et al. Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2022;36(7):e574\u2013e576.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1255_CR55","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jaad.2022.04.064","volume":"88","author":"SF Ruan","year":"2023","unstructured":"Ruan SF, Zhang LL, Liu Z, Lin TT, Wang HQ, Xu QY, et al. Real-world data on the clinical use of secukinumab in pediatric generalized pustular psoriasis: a 48-week retrospective study. J Am Acad Dermatol. 2023;88(1):243\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1255_CR56","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.3390\/jcm11072051","volume":"11","author":"T Hioki","year":"2022","unstructured":"Hioki T, Komine M, Ohtsuki M. Diagnosis and intervention in early psoriatic arthritis. J Clin Med. 2022;11(7):2051.","journal-title":"J Clin Med"},{"issue":"3","key":"1255_CR57","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","volume":"15","author":"JU Scher","year":"2019","unstructured":"Scher JU, Ogdie A, Merola JF, Ritchlin C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019;15(3):153\u201366.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"1255_CR58","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12016-017-8630-7","volume":"55","author":"A McArdle","year":"2018","unstructured":"McArdle A, Pennington S, FitzGerald O. Clinical features of psoriatic arthritis: a comprehensive review of unmet clinical needs. Clin Rev Allergy Immunol. 2018;55(3):271\u201394.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"1255_CR59","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","volume":"74","author":"M Haroon","year":"2015","unstructured":"Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1255_CR60","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3899\/jrheum.160115","volume":"43","author":"SY Paek","year":"2016","unstructured":"Paek SY, Thompson JM, Qureshi AA, Merola JF, Husni ME. Comprehensive assessment of the psoriasis patient (CAPP): a report from the GRAPPA 2015 annual meeting. J Rheumatol. 2016;43(5):961\u20134.","journal-title":"J Rheumatol"},{"issue":"10","key":"1255_CR61","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/acr.23171","volume":"69","author":"H Radner","year":"2017","unstructured":"Radner H, Lesperance T, Accortt NA, Solomon DH. Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis. Arthritis Care Res (Hoboken). 2017;69(10):1510\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"1255_CR62","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s40744-021-00378-w","volume":"8","author":"A Zabotti","year":"2021","unstructured":"Zabotti A, De Lucia O, Sakellariou G, Batticciotto A, Cincinelli G, Giovannini I, et al. Predictors, risk factors, and incidence rates of psoriatic arthritis development in psoriasis patients: a systematic literature review and meta-analysis. Rheumatol Ther. 2021;8(4):1519\u201334.","journal-title":"Rheumatol Ther"},{"issue":"10012","key":"1255_CR63","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","volume":"386","author":"LC Coates","year":"2015","unstructured":"Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O\u2019Dwyer JL, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. The Lancet. 2015;386(10012):2489\u201398.","journal-title":"The Lancet"},{"issue":"5","key":"1255_CR64","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3390\/ijms21051690","volume":"21","author":"M Kamata","year":"2020","unstructured":"Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21(5):1690.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1255_CR65","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13555-021-00650-5","volume":"12","author":"A Zabotti","year":"2022","unstructured":"Zabotti A, Giovannini I, McGonagle D, De Vita S, Stinco G, Errichetti E. Arthritis interception in patients with psoriasis treated with guselkumab. Dermatol Ther (Heidelb). 2022;12(1):5\u20138.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1255_CR66","doi-asserted-by":"crossref","unstructured":"Letarouilly JG, Sellam J, Richette P, Dieud\u00e9 P, Claudepierre P, Richard CM, et al. AB0760\u2005drug survival and efficacy of ustekinumab and secukinumab in psoriatic arthritis: a real-world multicentric cohort of 186 Patients. In: Abstracts accepted for Publication. BMJ Publishing Group Ltd and European League Against Rheumatism; 2019. pp. 1847.2\u20131848.","DOI":"10.1136\/annrheumdis-2019-eular.3279"},{"issue":"Suppl 1","key":"1255_CR67","doi-asserted-by":"publisher","first-page":"730.1","DOI":"10.1136\/annrheumdis-2020-eular.3702","volume":"79","author":"M Lorenzin","year":"2020","unstructured":"Lorenzin M, Carletto A, Foti R, Chimenti MS, Semeraro A, Costa L, et al. FRI0284\u2005Effectiveness and safety of secukinumab in na\u00efve or TNF-inhibitors failure psoriatic arthritis patients in real life: a 24-months prospective multicenter study. Ann Rheum Dis. 2020;79(Suppl 1):730.1-730.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"1255_CR68","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1136\/annrheumdis-2021-eular.2079","volume":"80","author":"H Marzo-Ortega","year":"2021","unstructured":"Marzo-Ortega H, Juanola X, Okano T, Schymura Y, Bradley A, Gerwien J, et al. POS0926 Normalisation of high sensitivity CRP versus clinical response to ixekizumab at week 16 in patients with radiographic& non-radiographic axial spondyloaarthritis: results from the coast studies. Ann Rheum Dis. 2021;80(Suppl 1):725\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"1255_CR69","doi-asserted-by":"publisher","first-page":"722.1","DOI":"10.1136\/annrheumdis-2020-eular.3197","volume":"79","author":"EG Favalli","year":"2020","unstructured":"Favalli EG, Marchesoni A, Balduzzi S, Montecucco C, Lomater C, Crepaldi G, et al. FRI0273\u2005Effectiveness and retention rate of secukinumab for psoriatic arthritis and axial spondyloarthritis: real-life data from the Italian Lohren Registry. Ann Rheum Dis. 2020;79(Suppl 1):722.1-723.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1255_CR70","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40744-024-00666-1","volume":"11","author":"AJ Kivitz","year":"2024","unstructured":"Kivitz AJ, Kremer JM, Legerton CW, Pricop L, Singhal A. Efficacy and safety of secukinumab in US patients with psoriatic arthritis: a subgroup analysis of the phase 3 FUTURE studies. Rheumatol Ther. 2024;11(3):675\u201389.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"1255_CR71","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s42358-023-00295-2","volume":"63","author":"F Molica Colella","year":"2023","unstructured":"Molica Colella F, Zizzo G, Parrino V, Filosa MT, Cavaliere R, Fazio F, et al. Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort. Adv Rheumatol. 2023;63(1):15.","journal-title":"Adv Rheumatol"},{"issue":"2020","key":"1255_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/6983272","volume":"31","author":"S Gentileschi","year":"2020","unstructured":"Gentileschi S, Rigante D, Sota J, Lopalco G, Giannotta MG, Emmi G, et al. Long-term effectiveness of secukinumab in patients with axial spondyloarthritis. Mediators Inflamm. 2020;31(2020):1\u20135.","journal-title":"Mediators Inflamm"},{"issue":"7","key":"1255_CR73","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/14712598.2020.1761957","volume":"20","author":"MS Chimenti","year":"2020","unstructured":"Chimenti MS, Fonti GL, Conigliaro P, Sunzini F, Scrivo R, Navarini L, et al. One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. Expert Opin Biol Ther. 2020;20(7):813\u201321.","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"1255_CR74","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaad.2004.04.014","volume":"51","author":"JM Gelfand","year":"2004","unstructured":"Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004;51(5):704\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1255_CR75","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1365-2133.1995.tb05019.x","volume":"132","author":"AY Finlay","year":"2006","unstructured":"Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 2006;132(2):236\u201344.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1255_CR76","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1186\/s12913-022-08954-8","volume":"22","author":"E Zagni","year":"2022","unstructured":"Zagni E, Frassi M, Mariano GP, Fusaro E, Lomater C, Del Medico P, et al. A real-world economic analysis of biologic therapies for psoriatic arthritis in Italy: results of the CHRONOS observational longitudinal study. BMC Health Serv Res. 2022;22(1):1537.","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"1255_CR77","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s13555-016-0114-9","volume":"6","author":"L Mantovani","year":"2016","unstructured":"Mantovani L, Medaglia M, Piacentini P, Tricca M, Vena GA, Vozza A, et al. Burden of moderate-to-severe plaque psoriasis and new therapeutic approaches (secukinumab): an Italian perspective. Dermatol Ther (Heidelb). 2016;6(2):151\u201367.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1255_CR78","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15166","author":"D Colombo","year":"2022","unstructured":"Colombo D, Bianchi L, Fabbrocini G, Corrao S, Offidani A, Stingeni L, et al. Real-world evidence of biologic treatments in moderate\u2013severe psoriasis in Italy: results of the CANOVA (effectiveness of biologic treatments for plaque psoriasis in Italy: an observational longitudinal study of real-life clinical practice) study. Dermatol Ther. 2022. https:\/\/doi.org\/10.1111\/dth.15166.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1255_CR79","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.det.2005.05.022","volume":"23","author":"DG Fortune","year":"2005","unstructured":"Fortune DG, Richards HL, Griffiths CEM. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin. 2005;23(4):681\u201394.","journal-title":"Dermatol Clin"},{"issue":"8","key":"1255_CR80","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/14712598.2019.1622678","volume":"19","author":"M Megna","year":"2019","unstructured":"Megna M, Di Costanzo L, Argenziano G, Balato A, Colasanti P, Cusano F, et al. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study. Expert Opin Biol Ther. 2019;19(8):855\u201361.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"1255_CR81","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/ph15010095","volume":"15","author":"G Damiani","year":"2022","unstructured":"Damiani G, Odorici G, Pacifico A, Morrone A, Conic RRZ, Davidson T, et al. Secukinumab loss of efficacy is perfectly counteracted by the introduction of combination therapy (rescue therapy): data from a multicenter real-life study in a cohort of italian psoriatic patients that avoided secukinumab switching. Pharmaceuticals. 2022;15(1):95.","journal-title":"Pharmaceuticals"},{"issue":"4","key":"1255_CR82","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/jdv.13478","volume":"30","author":"M Augustin","year":"2016","unstructured":"Augustin M, Abeysinghe S, Mallya U, Qureshi A, Roskell N, McBride D, et al. Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response\u2014results of a phase II regimen-finding trial. J Eur Acad Dermatol Venereol. 2016;30(4):645\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1255_CR83","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/ced.14258","volume":"45","author":"M Megna","year":"2020","unstructured":"Megna M, Camela E, Cinelli E, Fabbrocini G. Real-life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2-year period. Clin Exp Dermatol. 2020;45(7):848\u201352.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"1255_CR84","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/14740338.2023.2173170","volume":"22","author":"M Megna","year":"2023","unstructured":"Megna M, Camela E, Battista T, Genco L, Martora F, Noto M, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert Opin Drug Saf. 2023;22(1):25\u201341.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"1255_CR85","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/1346-8138.16551","volume":"50","author":"C Miao","year":"2023","unstructured":"Miao C, Chen Y, Wang Z, Xiang X, Liu Y, Xu Z. Real-world data on the use of secukinumab and acitretin in pediatric generalized pustular psoriasis. J Dermatol. 2023;50(2):258\u201361.","journal-title":"J Dermatol"},{"key":"1255_CR86","unstructured":"Di M.M.L. ACG, and CABP. Secukinumab in real life: a 2-year multicenter retrospective study in Campania region. i. Vol. 324. 8\u20139 p."},{"issue":"7","key":"1255_CR87","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/14712598.2018.1481503","volume":"18","author":"M Galluzzo","year":"2018","unstructured":"Galluzzo M, Talamonti M, De Simone C, D\u2019Adamio S, Moretta G, Tambone S, et al. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin Biol Ther. 2018;18(7):727\u201335.","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"1255_CR88","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1007\/s13555-022-00797-9","volume":"12","author":"C Pellegrini","year":"2022","unstructured":"Pellegrini C, Esposito M, Rossi E, Gisondi P, Piaserico S, Dapavo P, et al. Secukinumab in patients with psoriasis and a personal history of malignancy: a multicenter real-life observational study. Dermatol Ther (Heidelb). 2022;12(11):2613\u201326.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1255_CR89","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1080\/09546634.2019.1671577","volume":"31","author":"A Chiricozzi","year":"2020","unstructured":"Chiricozzi A, Balato A, Conrad C, Conti A, Dapavo P, Ferreira P, et al. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. J Dermatol Treat. 2020;31(5):476\u201383.","journal-title":"J Dermatol Treat"},{"issue":"4","key":"1255_CR90","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3899\/jrheum.190116","volume":"47","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Gladman DD, McInnes IB, Spindeldreher S, Martin R, Pricop L, et al. Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis. J Rheumatol. 2020;47(4):539\u201347.","journal-title":"J Rheumatol"},{"issue":"4","key":"1255_CR91","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31(4):299\u2013316.","journal-title":"BioDrugs"},{"key":"1255_CR92","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15697","author":"L Mastorino","year":"2022","unstructured":"Mastorino L, Roccuzzo G, Dapavo P, Siliquini N, Avallone G, Rubatto M, et al. Switching from IL23 inhibitors to IL17 inhibitors: a safe and effective practice? Dermatol Ther. 2022. https:\/\/doi.org\/10.1111\/dth.15697.","journal-title":"Dermatol Ther"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01255-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01255-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01255-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T13:07:41Z","timestamp":1728997661000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01255-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":92,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1255"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01255-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,24]]},"assertion":[{"value":"30 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Paolo Amerio declares the following conflicts of interest: Novartis, Sanofi, Jannsen, Eli Lilly, Galderma. Laura Atzori has been consultant, PI, speaker for Abbvie, Novartis, Janssen, UCB Pharma, Sanofi Genzyme, Lilly, Pfizer, Almirall, BMS. Anna Balato has served on Scientific Boards and\/or has received fees for Scientific Consultations from: Abbvie, Amgen, Boehringer Ingelheim, Janssen, Eli-Lilly, Novartis, UCB. Luca Bianchi has been consultant, PI, speaker for Abbvie, Novartis, Janssen, UCB Pharma, Sanofi Genzyme, Lilly, Pfizer, Almirall, Sun Pharma, BMS. Andrea Chiricozzi has served as advisory board member and consultant and has received fees and speaker's honoraria or has participated in clinical trials for AbbVie, Almirall, Bristol Myers Squibb, Leo Pharma, Lilly, Janssen, Novartis, Pfizer and Sanofi Genzyme. Antonio Costanzo has been principal investigator in clinical trials sponsored by and\/or and has received personal fees for participation in advisory board from Abbvie, Almirall, Amgen, Boehringer, BMS, Leo Pharma, Lilly, Novartis, Pfizer, UCB and Sanofi, outside the submitted work. Maria Concetta Fargnoli has served on advisory boards, received honoraria for lectures and\/or research grants from AMGEN, Almirall, Abbvie, Boehringer-Ingelheim, BMS, Galderma, Kyowa Kyrin, Leo Pharma, Pierre Fabre, UCB, Lilly, Pfizer, Janssen, MSD, Novartis, Sanofi-Regeneron, Sunpharma. Claudia Giofr\u00e8 has served as advisory board member or has received fees and speaker or has participated in clinical trials for Amgen, Novartis, Janssen, Leo Pharma, Almirall, Abbvie, UCB, Lilly. Paolo Gisondi declares the following conflicts of interest: Amgen, Almirall Abbvie Eli Lilly Novartis Janssen UCB Pierre Fabre Pfizer. Claudio Guarneri declares the following conflicts of interest: Pfizer, Abbvie, Janssen, Novartis, Merck-Serono, Eli-Lilly, Celgene, Leo Pharma, Leo Pharma Denmark, Almirall, Amgen, Sanofi-Aventis, Boehringer-Ingelheim, Bristol Myers Squibb, UCB Pharma. Serena Lembo declares the following conflicts of interest: Pfizer, Abbvie, Janssen, Novartis, Eli-Lilly, Leo Pharma, Almirall, Sanofi-Aventis, UCB Pharma. Santo Raffaele Mercuri SRM has been principal investigator in clinical trials sponsored by and\/or has received personal fees for participation in advisory board from Abbvie, Almirall, Amgen, Leopharma, Lilly, Jansenn, Novartis, Sanofi and Ucb, outside the submitted work. Pietro Morrone has served as advisory board member or has received fees and speaker for AbbVie, Almirall,Novartis, Sanofi Genzyme, Lilly, Leo Pharma. Giovanni Palazzo declares the following conflicts of interest: Novartis, Abbvie, Leopharma, Lilly, Pfizer, Janssen. Aurora Parodi declares the following conflicts of interest: Almirall, Abbvia, Amgen, Novartis, Pfizer, Lilly, LEO pharma, Euroimmun, Argx, Menarini, Boehringer. Giovanni Pellacani received institutional grants and\/or honoraria for Advisory boards: Abbvie, Galderma, Leo-pharma, Lilly, Pfizer, Novartis, Sanofi, UCB. Stefano Piaserico has been a consultant and\/or speaker for Abbvie, Almirall, Amgen, Janssen, LEO Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, andUCB. Francesca Prignano served as consultant, presenter and advisory board member for Abbvie, Novartis, Eli-Lilly, Jannsen-Cilag, Bohringer- Ingelheim, Almirall, Leo-Pharma, UCB, Bristol-Meyers-Squibb. Marco Romanelli: Abbvie, Lilly, Novartis, URGO, ConvaTec. Paola Savoia has served as advisory board member or has received fees and speaker's honoraria or has participated in clinical trials for AbbVie, Almirall, Bristol Myers Squibb, Ganassini, Kyowa Kirin, Janssen, Novartis, Sanofi and Sunpharma. Luca Stingeni has been principal investigator in clinical trials sponsored by and\/or and has received personal fees for participation in advisory board from Abbvie, Leo Pharma, Lilly, Novartis, Pfizer, and Sanofi, outside the submitted work. Emanuele Trovato: Speaker for Abbvie, Novartis, Janssen, UCB Pharma, Eli-Lilly, Almirall, Leo Pharma. Marina Venturini has served as advisory board member and consultant and has received fees and speaker's honoraria or has participated in clinical trials for AbbVie, Almirall, Bristol Myers Squibb, Boehringer-Ingelheim, Eli Lilly, Galderma, Janssen, Leo Pharma, Novartis, Pierre Fabre, UCB Pharma. Leonardo Zichichi has been consultant, and speaker for Abbvie, Novartis, Janssen, Sanofi Genzyme, Lilly, Almirall, Sun Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}